OS Therapies Incorporated, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $6.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding OS Therapies Incorporated’s regulatory strategy and promising clinical data. The company has prioritized its UK MHRA submission for OST-HER2, which is a strategic move given the MHRA’s alignment on using historical control arms in their Phase 2b trial. This alignment provides a clearer pathway to conditional approval in the UK, offering a degree of certainty that is currently more favorable than the FDA’s stance.
Additionally, OST-HER2 has shown promising results in treating recurrent osteosarcoma, with the potential to significantly impact survival rates. The therapy’s design, which targets HER2-expressing cancer cells, has garnered FDA Orphan, Fast Track, and Rare Pediatric Disease designations, enhancing its potential for expedited review processes. If approved, the therapy could also secure a priority review voucher, representing a substantial opportunity for non-dilutive capital. These factors collectively contribute to the positive outlook and the Buy rating for OSTX.
McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, Medicus Pharma Ltd, and Kairos Pharma, Ltd.. According to TipRanks, McCarthy has an average return of -17.7% and a 31.66% success rate on recommended stocks.